Glimepiride 2mg, Ploglitozone Hcl 15mg + Metformin Hcl (Extended Reledsed) 500mg Tablets (uncoted bilayered)

Glimepiride 2mg, Ploglitozone Hcl 15mg + Metformin Hcl (Extended Reledsed) 500mg Tablets (uncoted bilayered) is a bilayered tablet formulated with Glimepiride 2mg, Ploglitozone Hcl 15mg + Metformin Hcl (Extended Reledsed) 500mg (uncoted ). The listed active ingredient profile is Glimepiride; Ploglitozone Hcl; Metformin Hcl, placing the product in the oral antidiabetic category. The formulation contains one or more oral glucose-lowering medicines used in clinician-directed management of type 2 diabetes mellitus. The source indicates bilayered characteristics, which should be retained exactly because release technology can affect administration and product performance. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.